top of page
jumbo phages have unique
biological properties of high
potential to develop novel
technologies targeting top priority AMR pathogens
News & PRess
> july '24
phage therapy in uruguay
Adressing Antibiotic- Resistant Infections
This year, Kinzbio received its first request for the treatment of a patient in ICU with a persistent pulmonary colonization by Pseudomonas aeruginosa, for which all available antibiotic treatments had failed. The team developed a personalized phage-based treatment that succeeded in eliminating the bacteria in just four days.
​​
Currently, Kinzbio has completed its fourth treatment in the country, all of them successfully.
unleashing the potential of
Jumbo phages
together
Kinzbio fosters collaborations and partnerships with pharma leaders, clinical organizations, academic labs and funding agencies to help the company to accelerate the development of its jumbo phage platform and pipeline.
Kinzbio has an open communication channel with and is always seeking to hear from industry partners and funding institutions interested in joining efforts to keep developing applications based on the biology of jumbo phages.
BE IN
TOUCH
Please fill your contact details below:
Phage technologies for a
healthier world
ANtimicrobial
resistance is one
of the major global
health issues that
humanity is facing
every year millions
of lives are lost and
billions are spent in
prevention and
treatment of AMR
phages are natural
bacterial killers
that can be used to
combat AMR pathogens
News
Partnering
Contact
bottom of page